SBI-477

• Description:

  SBI-477 is a chemical probe that stimulates insulin signaling by deactivating the transcription factor MondoA. SBI-477 can lead to reduced expression of the insulin pathway suppressors thioredoxin-interacting protein (TXNIP) and arrestin domain-containing 4 (ARRDC4) . SBI-477 coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes[1].

• UNSPSC:

  12352005

• Target:

  Arrestin; Fluorescent Dye; Insulin Receptor; LXR

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Metabolic Enzyme/Protease; Others; Protein Tyrosine Kinase/RTK; Vitamin D Related/Nuclear Receptor

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/sbi-477.html

• Concentration:

  10mM

• Purity:

  98.0

• Solubility:

  DMSO : 65 mg/mL (ultrasonic)

• Smiles:

  O=C(NC1=NC(C2=CC=C(OC)C=C2)=CS1)C3=CC=C(OCC(N4CCOCC4)=O)C(OC)=C3

• Molecular Formula:

  C24H25N3O6S

• Molecular Weight:

  483.54

• References & Citations:

  [1]Ahn B, et al. MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling. J Clin Invest. 2016 Sep 1;126 (9) :3567-79.|[2]Nakayama, Y., et al., (2024) . Systemic Deletion of ARRDC4 Improves Cardiac Reserve and Exercise Capacity in Diabetes. Circulation research, 135 (3), 416–433.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [781628-99-7]